Loading...
CAMX logo

Camurus AB (publ)OM:CAMX Stock Report

Market Cap SEK 28.0b
Share Price
SEK 471.20
n/a
1Y-22.4%
7D-2.1%
Portfolio Value
​
View

Camurus AB (publ)

OM:CAMX Stock Report

Market Cap: SEK 28.0b

Camurus (CAMX) Stock Overview

A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. More details

CAMX fundamental analysis
Snowflake Score
Valuation5/6
Future Growth6/6
Past Performance5/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 65% below our estimate of its fair value

Earnings are forecast to grow 32.92% per year

Earnings grew by 71.7% over the past year

Analysts in good agreement that stock price will rise by 63%

Risk Analysis

CAMX passed our risk checks.

CAMX Community Fair Values

Create Narrative

See what 56 others think this stock is worth. Follow their fair value or set your own to get alerts.

CAMX logo
Camurus

Global Expansion And Regulatory Approvals Will Transform Healthcare Delivery

Key Takeaways Expansion in innovative long-acting treatments, supported by favorable regulations and partnerships, positions Camurus for broad market penetration and stable recurring revenues. Strong clinical pipeline and financial flexibility enhance potential for sustained margin growth, product launches, and strategic investment opportunities.
View narrative
SEK 814.17
FV
42.1% undervalued intrinsic discount
33.55%
Revenue growth p.a.
256
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
32users have followed this narrative
CAMX logo
Camurus

Rising Global Scrutiny And Generic Competition Will Pressure Pharma Margins

Key Takeaways Global price controls and rising generic competition threaten Camurus' ability to sustain premium pricing and stable margins on core products. Heavy dependence on a few specialty drugs exposes the company to regulatory, reimbursement, and market exclusivity risks, impacting future earnings growth.
View narrative
SEK 660
FV
28.6% undervalued intrinsic discount
35.83%
Revenue growth p.a.
46
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
CAMX logo
Camurus

Rising Chronic Disease Trends Will Drive Long-Acting Drug Adoption Globally

Key Takeaways Rapid adoption in key therapies and markets, alongside innovation in delivery platforms, positions Camurus for outperformance in revenue and market share. Strategic partnerships, strong financials, and M&A readiness support long-term earnings growth and diversification beyond analyst expectations.
View narrative
SEK 930
FV
49.3% undervalued intrinsic discount
57.18%
Revenue growth p.a.
14
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
View Stock Community
UNCY logo
Unicycive Therapeutics

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

View narrative
4.3k
users have viewed this narrative
15users have liked this narrative
0users have commented on this narrative
85users have followed this narrative
US$21.53
68.3% undervalued intrinsic discount
Fair Value
Profit Margin
20%
Future PE
27x
Price in 2030
US$34.67

Camurus AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Camurus
Historical stock prices
Current Share PriceSEK 468.20
52 Week HighSEK 754.50
52 Week LowSEK 465.00
Beta0.40
1 Month Change-15.41%
3 Month Change-21.24%
1 Year Change-22.42%
3 Year Change117.97%
5 Year Change121.90%
Change since IPO609.39%

Recent News & Updates

These Analysts Just Made A Sizeable Downgrade To Their Camurus AB (publ) (STO:CAMX) EPS Forecasts

Feb 18
These Analysts Just Made A Sizeable Downgrade To Their Camurus AB (publ) (STO:CAMX) EPS Forecasts

Recent updates

These Analysts Just Made A Sizeable Downgrade To Their Camurus AB (publ) (STO:CAMX) EPS Forecasts

Feb 18
These Analysts Just Made A Sizeable Downgrade To Their Camurus AB (publ) (STO:CAMX) EPS Forecasts

Camurus AB (publ)'s (STO:CAMX) Intrinsic Value Is Potentially 69% Above Its Share Price

Dec 08
Camurus AB (publ)'s (STO:CAMX) Intrinsic Value Is Potentially 69% Above Its Share Price

Analysts Have Just Cut Their Camurus AB (publ) (STO:CAMX) Revenue Estimates By 11%

Nov 19
Analysts Have Just Cut Their Camurus AB (publ) (STO:CAMX) Revenue Estimates By 11%

Here's What Analysts Are Forecasting For Camurus AB (publ) (STO:CAMX) Following Its Earnings Miss

Nov 09
Here's What Analysts Are Forecasting For Camurus AB (publ) (STO:CAMX) Following Its Earnings Miss

If EPS Growth Is Important To You, Camurus (STO:CAMX) Presents An Opportunity

Oct 19
If EPS Growth Is Important To You, Camurus (STO:CAMX) Presents An Opportunity

Should You Be Adding Camurus (STO:CAMX) To Your Watchlist Today?

Jun 10
Should You Be Adding Camurus (STO:CAMX) To Your Watchlist Today?

There May Be Underlying Issues With The Quality Of Camurus' (STO:CAMX) Earnings

May 23
There May Be Underlying Issues With The Quality Of Camurus' (STO:CAMX) Earnings

There's No Escaping Camurus AB (publ)'s (STO:CAMX) Muted Revenues Despite A 27% Share Price Rise

May 08
There's No Escaping Camurus AB (publ)'s (STO:CAMX) Muted Revenues Despite A 27% Share Price Rise

Camurus AB (publ)'s (STO:CAMX) Popularity With Investors Is Under Threat From Overpricing

Mar 09
Camurus AB (publ)'s (STO:CAMX) Popularity With Investors Is Under Threat From Overpricing
User avatar

Buvidal And Brixadi Expansion To Fuel Revenue Growth And Boost Profit Margins

Strong R&D pipeline and successful regulatory progress signal future revenue growth from new treatments entering various markets.

Camurus AB (publ)'s (STO:CAMX) P/S Is On The Mark

Dec 07
Camurus AB (publ)'s (STO:CAMX) P/S Is On The Mark

Investors Can Find Comfort In Camurus' (STO:CAMX) Earnings Quality

Nov 15
Investors Can Find Comfort In Camurus' (STO:CAMX) Earnings Quality

Camurus AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Nov 10
Camurus AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

What Camurus AB (publ)'s (STO:CAMX) P/S Is Not Telling You

Aug 09
What Camurus AB (publ)'s (STO:CAMX) P/S Is Not Telling You

Earnings Miss: Camurus AB (publ) Missed EPS By 11% And Analysts Are Revising Their Forecasts

Jul 19
Earnings Miss: Camurus AB (publ) Missed EPS By 11% And Analysts Are Revising Their Forecasts

We Ran A Stock Scan For Earnings Growth And Camurus (STO:CAMX) Passed With Ease

Jul 12
We Ran A Stock Scan For Earnings Growth And Camurus (STO:CAMX) Passed With Ease

Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

May 02
Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

Investors Appear Satisfied With Camurus AB (publ)'s (STO:CAMX) Prospects

Apr 19
Investors Appear Satisfied With Camurus AB (publ)'s (STO:CAMX) Prospects

Camurus' (STO:CAMX) Strong Earnings Are Of Good Quality

Feb 22
Camurus' (STO:CAMX) Strong Earnings Are Of Good Quality

With EPS Growth And More, Camurus (STO:CAMX) Makes An Interesting Case

Feb 17
With EPS Growth And More, Camurus (STO:CAMX) Makes An Interesting Case

Shareholder Returns

CAMXSE PharmaceuticalsSE Market
7D-2.1%-1.0%0.5%
1Y-22.4%-22.3%2.9%

Return vs Industry: CAMX matched the Swedish Pharmaceuticals industry which returned -22.3% over the past year.

Return vs Market: CAMX underperformed the Swedish Market which returned 2.9% over the past year.

Price Volatility

Is CAMX's price volatile compared to industry and market?
CAMX volatility
CAMX Average Weekly Movement8.8%
Pharmaceuticals Industry Average Movement8.8%
Market Average Movement6.4%
10% most volatile stocks in SE Market12.4%
10% least volatile stocks in SE Market3.5%

Stable Share Price: CAMX has not had significant price volatility in the past 3 months compared to the Swedish market.

Volatility Over Time: CAMX's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1991285Fredrik Tibergwww.camurus.com

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon.

Camurus AB (publ) Fundamentals Summary

How do Camurus's earnings and revenue compare to its market cap?
CAMX fundamental statistics
Market capSEK 27.97b
Earnings (TTM)SEK 735.57m
Revenue (TTM)SEK 2.27b
38.0x
P/E Ratio
12.3x
P/S Ratio

Is CAMX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CAMX income statement (TTM)
RevenueSEK 2.27b
Cost of RevenueSEK 156.14m
Gross ProfitSEK 2.11b
Other ExpensesSEK 1.37b
EarningsSEK 735.57m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

Apr 29, 2026

Earnings per share (EPS)12.31
Gross Margin93.11%
Net Profit Margin32.47%
Debt/Equity Ratio0%

How did CAMX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/16 16:20
End of Day Share Price 2026/03/13 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Camurus AB (publ) is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB
Gonzalo Artiach CastanonDanske Bank
Kristofer Liljeberg-SvenssonDNB Carnegie